Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by HC Wainwright

Sutro Biopharma (NASDAQ:STRO) was upgraded by analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm currently has a $28.00 price objective on the stock, up from their prior price objective of $10.00. HC Wainwright’s target price would suggest a potential upside of 19.15% from the company’s current price. HC Wainwright also issued estimates for Sutro Biopharma’s FY2030 earnings at ($4.43) EPS.

STRO has been the subject of several other reports. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th. Wedbush reaffirmed a “neutral” rating and issued a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sutro Biopharma in a research note on Wednesday, December 17th. Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price objective for the company in a research note on Tuesday, January 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a report on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Sutro Biopharma currently has an average rating of “Hold” and an average target price of $37.29.

Sutro Biopharma Trading Down 0.3%

Shares of STRO stock opened at $23.50 on Tuesday. The firm has a fifty day simple moving average of $18.61 and a two-hundred day simple moving average of $12.76. Sutro Biopharma has a 12 month low of $5.23 and a 12 month high of $26.54. The firm has a market capitalization of $199.99 million, a PE ratio of -0.90 and a beta of 1.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Bridgeway Capital Management LLC grew its position in Sutro Biopharma by 232.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock worth $37,000 after purchasing an additional 30,000 shares in the last quarter. Invesco Ltd. lifted its position in shares of Sutro Biopharma by 137.8% during the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock worth $60,000 after buying an additional 53,390 shares in the last quarter. Cerity Partners LLC boosted its stake in shares of Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock worth $75,000 after buying an additional 66,372 shares during the last quarter. Qube Research & Technologies Ltd purchased a new position in shares of Sutro Biopharma in the 2nd quarter worth approximately $82,000. Finally, State of Tennessee Department of Treasury bought a new position in shares of Sutro Biopharma in the fourth quarter valued at approximately $86,000. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Key Sutro Biopharma News

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55 (from $51) and kept a Buy rating — a materially higher target that suggests strong upside vs. the current share price and supports bullish investor expectations. Deutsche Bank raises PT to $55
• Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and raised its price target to $27 (from $8), signaling improving institutional sentiment and providing a nearer-term upside anchor for the stock. Wells Fargo upgrade
• Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its target to $28 (from $10). The firm also published FY2030 EPS projections (large negative EPS expected), but maintained a Buy stance and higher target — a supportive signal from a biotech-focused shop. HC Wainwright upgrade HC Wainwright EPS note
• Neutral Sentiment: Short-interest reports for March show anomalous values (reported as 0 shares with NaN changes and 0.0 days-to-cover across different volume baselines). The data appears unreliable or reflects a reporting/clearing event, so its immediate impact on price is unclear. (Multiple internal short-interest notices consolidated)

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.